about
Acamprosate: a prototypic neuromodulator in the treatment of alcohol dependenceThe development of acamprosate as a treatment against alcohol relapseThe clinical pharmacology of acamprosate.Acamprosate: A Review of Its Use in Alcohol DependenceAcamprosate Is Neuroprotective Against Glutamate-Induced Excitotoxicity When Enhanced by Ethanol Withdrawal in Neocortical Cultures of Fetal Rat BrainAcamprosate in a mouse model of fragile X syndrome: modulation of spontaneous cortical activity, ERK1/2 activation, locomotor behavior, and anxietyAcamprosate.The neurobiology, clinical efficacy and safety of acamprosate in the treatment of alcohol dependence.Acamprosate-induced Extrapyramidal Symptoms in an Elderly Patient with Alcohol Dependence.Six-month outcome in bipolar spectrum alcoholics treated with acamprosate after detoxification: a retrospective study.Flip-flop pharmacokinetics--delivering a reversal of disposition: challenges and opportunities during drug developmentAcamprosate for the adjunctive treatment of alcohol dependence.Acamprosate for treatment of alcohol dependence: mechanisms, efficacy, and clinical utility.Few Drugs Display Flip-Flop Pharmacokinetics and These Are Primarily Associated with Classes 3 and 4 of the BDDCSAn analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate.Acamprosate in the treatment of alcohol dependence.Pharmacotherapy for alcohol dependence: anticraving medications for relapse prevention.Safety and efficacy of acamprosate for the treatment of alcohol dependence.Acamprosate in the treatment of alcohol dependence: clinical and economic considerations.Acamprosate: a new tool in the battle against alcohol dependence.Acamprosate modulates experimental autoimmune encephalomyelitis.Acamprosate has no effect on NMDA-induced toxicity but reduces toxicity induced by spermidine or by changing the medium in organotypic hippocampal slice cultures from rat.Disposition of acamprosate in the rat: influence of probenecid.Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors.The neurotoxicity induced by ethanol withdrawal in mature organotypic hippocampal slices might involve cross-talk between metabotropic glutamate type 5 receptors and N-methyl-D-aspartate receptors.Understanding and treating alcohol dependence.Alcohol effects during acamprosate treatment: a dose-response study in humans.[The pharmacologic treatment of the alcohol dependence].A microdialysis study of extracellular levels of acamprosate and naltrexone in the rat brain following acute and repeated administration.The acute anti-craving effect of acamprosate in alcohol-preferring rats is associated with modulation of the mesolimbic dopamine system.Effects of acamprosate on sleep during alcohol withdrawal: A double-blind placebo-controlled polysomnographic study in alcohol-dependent subjects.A randomized, double-blind, placebo-controlled clinical trial of acamprosate in alcohol-dependent individuals with bipolar disorder: a preliminary report.
P2860
Q24595863-EC07A009-619C-42E0-8A0B-604096084CF9Q26862199-CFC6FF9F-6FEB-45FC-8FE2-585E5E29BC6DQ27687874-15CA97C5-80AC-41D5-ADF1-33153C3F0877Q28263633-44198DAA-1546-4793-B0C1-CB66302F7E2DQ29037451-CFA01788-88EB-41A4-B27C-A153288537FDQ30855390-D025BD70-E674-4A46-9C67-8B6E646966CCQ33531891-CD187EBB-4D0C-4369-A2E2-AFFD4DF1ABF2Q34088940-F54DC7DE-FD26-475D-A5F8-825257DDAAC9Q34129873-28158F52-A2F2-4605-84D7-3CCF9312B327Q34773574-DC6A326F-210E-4C8C-BFC7-0C2DCAA63E93Q35153417-ED49F531-6214-40EE-8FA3-76E4DE989612Q35169452-3D1757E8-8E73-4E69-81F0-B296FCCDD692Q35752035-7CCFC2F8-797E-4BFE-B12A-039EA047A517Q35952140-EA6FAB2E-020D-446F-8A1A-EA8DB5FF226EQ36145548-6ABC065B-86E2-44F8-BCC8-9B882EFA7342Q36273459-E1E9158E-07F5-4708-BA1C-A3933EB0ACD5Q36461774-22AF8C5F-7ADD-41E2-A2AB-DB139C26D161Q36590706-A8083447-D20B-4949-BD84-B20F8AB3E9B4Q36998827-70A96F05-B74E-40A0-AA9D-691BE8D47A9BQ37166144-7D537BB7-F1F3-4C14-99B2-5F6264C50A56Q39686256-A411357C-D70B-4DBB-82AA-434791B36F32Q44015267-BAAB9146-092B-4AD9-A7A4-46273629D129Q44159889-FD1A9EBA-52F3-4CC6-8CEE-E77D45E0ADFCQ44261091-8A3708E1-97ED-455A-98E6-A346E1728671Q44666716-679C657D-6E56-4D03-AA03-095684941E7BQ44917574-1118B28F-C3FA-440E-894D-ACEEE1675C62Q44977111-A4FBC91A-EAD7-4FF5-A4C4-D51217CFB1EDQ45281456-60886EB9-1F34-47AB-9925-FD7ACDF8F415Q46198423-A086D53B-E85F-44F7-8D19-293CD6226D48Q46658074-345C56E2-93C1-44FB-95DE-B500756EE7B8Q48492178-27F12308-782A-48C3-AB2B-26FFCBBDB3D9Q48732780-06AFF509-97CF-466F-A41C-FE98515101EF
P2860
description
1998 nî lūn-bûn
@nan
1998 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Clinical pharmacokinetics of acamprosate
@ast
Clinical pharmacokinetics of acamprosate
@en
Clinical pharmacokinetics of acamprosate
@nl
type
label
Clinical pharmacokinetics of acamprosate
@ast
Clinical pharmacokinetics of acamprosate
@en
Clinical pharmacokinetics of acamprosate
@nl
prefLabel
Clinical pharmacokinetics of acamprosate
@ast
Clinical pharmacokinetics of acamprosate
@en
Clinical pharmacokinetics of acamprosate
@nl
P2093
P1476
Clinical pharmacokinetics of acamprosate
@en
P2093
P304
P356
10.2165/00003088-199835050-00001
P407
P577
1998-11-01T00:00:00Z
P6179
1035599811